Intradermal immunotherapy with low-dose house dust mite allergens in patients with allergic rhinitis: A proof-of-concept study

Vieira-Hernández, Alberto; Capriles‐Hulett, Arnaldo; Sánchez‐Borges, Mario; Fabiano, Fabiola; Albarrán-Barrios, Carlos

doi:10.29262/ram.v65i1.322

Cited by 9 publications

(11 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was verified in murine models, using ovalbumin as an immunogen in the absence of adjuvant 18 . Similar results have been described in humans using pollen allergen extracts from Phleum pratense , administered intradermally at low doses, 19 and, more recently, with mite extracts 20 . The WHO recommends the ID instead of the IM administration, as in the case of the rabies vaccine 21…”

Section: Introductionsupporting

confidence: 65%

“…18 Similar results have been described in humans using pollen allergen extracts from Phleum pratense, administered intradermally at low doses, 19 and, more recently, with mite extracts. 20 The WHO recommends the ID instead of the IM administration, as in the case of the rabies vaccine. 21 We have previously conducted two phase II clinical trials with an allergoid of P pratense administered intradermally (EudraCT 2014-004429-42 and 2012-003319-79).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intradermal Phleum pratense allergoid immunotherapy. Double‐blind, randomized, placebo‐controlled trial

Martínez

Jiménez

García

et al. 2020

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 65%

Section: Introductionmentioning

confidence: 99%

Intradermal Phleum pratense allergoid immunotherapy. Double‐blind, randomized, placebo‐controlled trial

Martínez

Jiménez

García

et al. 2020

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…For Blomia tropicalis allergens, 0.12 mcg (120 ng/0.05 mL) were correspondingly estimated. These concentrations were guided by previous clinical results obtained with this technique 32 and the IgG4 responses resulting from Dp/Df major allergens showed a trend for improvement after 3-month treatment, though found not to be statistically significant. Though increasing the dose of Dp/Df seemed logical (from 5 ng/0.05 mL to 50 ng/0.05 mL per allergy shot), we still maintained a low-dose range objective (Appendix A).…”

Section: Treatment Compoundingmentioning

confidence: 99%

“…23,24 Several articles concerning the intradermal route technique administration (IDR) have been published. [25][26][27][28][29][30][31] We have reported in a real-life pilot study 32 the effectiveness and tolerance of a particular intradermal technique for Dermatophagoides mites and Blomia tropicalis allergens. Herein, we are expanding our results, over a year, in a greater number of allergic rhinitis children.…”

Section: Introductionmentioning

confidence: 99%

Aqueous intradermal low-dose house dust mite immunotherapy in tropical settings: a valid cost-effective approach for developing nations?

Rondon

Sánchez‐Borges

Cupello³

et al. 2021

aei

Self Cite

View full text Add to dashboard Cite

Introduction: Aqueous allergen injections, an effective and century-old technique, is considered a second-line approach in daily clinical practice. Inconveniences still surround conventional subcutaneous immunotherapy (SCIT) administration, such as a need for frequent injections, prolonged up-dosing schedules, elevated costs, and the unlikely possibility of a systemic reaction. The intradermal immunotherapy route (IDR) might favorably impact many of the aforementioned issues (Table 1). House dust mite (HDM) allergens are the main perennial sensitizers in the tropics, and as such, are solely employed in immunotherapy treatments. Methods: We carried out a year-long real-life study in 25 perennial allergic rhinitis children, symptomatic on exposure to house dust, employing an intradermal low-dose allergen mix consisting of 50 ng of Dermatophagoides pteronyssinus/Dermatophagoides farinae and 120 ng of Blomia tropicalis, under a unique cost-wise protocol. Basal symptoms/signs and face Visual Analog Scale (fVAS) scores were recorded for 2 weeks and later compared with those registered throughout the 1-year treatment. Serum-specific IgG4 and IL-10 levels were employed in the assessment of the immune responses.Results: Symptoms/signs and fVAS scores were significantly reduced from days 42 and 49, respectively, and remained so until treatment completion. Increases in specific IgG4’s and IL-10 levels reflected significant immune responses. Injections were well tolerated and families reported improved health status (quality of life, QoL).Conclusions: A unique cost-effective immunotherapy alternative for deprived allergic communities in tropical settings is depicted; further research is needed.

show abstract

“…The latter is characteristic of Latin American countries, with few studies addressing its use in immunotherapy with this house dust mite. Vieira-Hernández et al 12 demonstrated the effectiveness of intradermal immunotherapy with low doses of Dp/Df and Bt. 13 …”

Section: Introductionmentioning

confidence: 99%

Satisfaction of allergic patients treated with house dust mite sublingual immunotherapy

Aarestrup¹,

Aarestrup

Andrade³

et al. 2021

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Sublingual immunotherapy (SLIT) has been used for more than three decades as a therapeutic strategy for the treatment of allergic diseases. Studies have demonstrated its efficacy and safety, and numerous clinical trials have evaluated these parameters. In the present study, through patient perception, we investigated the patient satisfaction with the use of house dust mite SLIT treatment. “Satisfaction Scale for Patients Receiving Allergen Immunotherapy” (ESPIA) questionnaire, a standardized and validated instrument for clinical studies evaluating allergen immunotherapy, was applied to allergic patients ( N = 136). Children and adults of both sexes who received SLIT for Dermatophagoides pteronyssinus and/or Blomia tropicalis, according to the results of an immediate reading puncture test, were included. Data analysis showed that the perception of treatment effectiveness was 92%, performance improvement in the daily activities was 91%, a satisfactory cost-benefit balance was 84%, and the perception of general satisfaction was 97%. The results showed a high perception of satisfaction in allergic patients undergoing house dust mite SLIT.

show abstract

Intradermal immunotherapy with low-dose house dust mite allergens in patients with allergic rhinitis: A proof-of-concept study

Cited by 9 publications

References 37 publications

Intradermal Phleum pratense allergoid immunotherapy. Double‐blind, randomized, placebo‐controlled trial

Intradermal Phleum pratense allergoid immunotherapy. Double‐blind, randomized, placebo‐controlled trial

Aqueous intradermal low-dose house dust mite immunotherapy in tropical settings: a valid cost-effective approach for developing nations?

Satisfaction of allergic patients treated with house dust mite sublingual immunotherapy

Contact Info

Product

Resources

About